Inflammation BiomarkersRESINCANCT07395921
Resveratrol Effects on Inflammatory Biomarkers and Cardiometabolic Parameters.
A study testing RES 120, RES 250 and RES 500 in people with Inflammation Biomarkers and Cardiometabolic Health Indicators, run by Center for Research and Innovation Viña Concha y Toro at 1 site in Chile.
Trial summary
This study aims to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers and cardiometabolic parameters in community-dwelling adults Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Inflammation Biomarkers, Cardiometabolic Health Indicators, Antioxidant Status, Inflammation
- What is being tested?
- RES 120, RES 250 and RES 500
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 75 participants
- Where
- 1 siteChile
- Study dates
- 1 Jun 2026to 1 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Comunnity-dwelling persons.
- Any ethnicity.
- With willingness to consume the bar daily during the intervention period.
Who cannot join
- Allergy/intolerance to ingredients in the bar.
- Pregnancy or breastfeeding.
- Use of antioxidant/polymeroid supplements in the last 4 weeks.
- Unstable chronic diseases (e.g., severe liver failure, advanced kidney failure, active cancer).
- Persons in treatments that strongly interfere with polyphenol metabolism (e.g., antibiotics, anti-inflammatories, corticosteroids, anti-allergy medication).
- Persons with metal prosthesis.
Show all 10Show fewer
- Persons undergoing or waiting for metabolic bariatric surgery.
- Persons with scheduled digestive surgery within the next 8 weeks
- Persons in recent treatments for hypertension (less than 3 month).
- Participation in another clinical trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Chile1 site
Universidad Católica del Maule
Talca, Maule Region
Dr. Ileana González Bonet
About this study
Official title: Effects of Resveratrol Supplementation on Inflammatory Biomarkers and Cardiometabolic Parameters in Community-dwelling Adults. (RESINCA-trial)
This study aims to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers and cardiometabolic parameters in community-dwelling adults
Read the detailed description
Three groups will be studied: control group (RES 120), experimental group 1 (RES 250) and experimental group 2 (RES 500).
During 8 weeks the RES 120 group will received daily one grape pomace bars with 120 mg of total polyphenols contents (TPC), the RES 250 group will received daily one grape pomace bars enriched with resveratrol until reach 250 mg of TPC and the RES 500 group will received daily one grape pomace bars enriched with resveratrol until reach 500 mg of TPC.
Outcomes will be assessed at baseline and after 8 weeks.
At the end of the study, the groups that shows less o no effects will be invited to enjoy the bar showing to be more effective.
Primary outcomes are: Total plasma antioxidant capacity (TAC), ultra-sensitivity CRP, IL-6, TNF-alfa, plasma malondialdehyde and AGEs.
Secondary outcomes are: body weight, Body Mass Index (BMI), basal metabolic rate, fat mass, skeletal muscle mass, and waist-to-hip ratio. Handgrip strength, 30-second sit-to-stand test, and heart rate variability. Fasting insulin, fasting glucose, HOMA-IR. Lipid profile, liver profile, blood pressure.
All procedures will be performed at the clinical simulation center of the Faculty of Medicine of the Catholic University of Maule.
The sample size was estimated under the following criteria, using G*Power software (version 3.1):
Primary outcome: Total Plasma Antioxidant Capacity (TAC). Type of comparison: differences between parallel groups. Level of significance (α): 0.05 (bilateral). Stat (1 - β): 80%. Minimum expected difference (Δ): 0.25 TAC units. Standard deviation (σ): 0.30 TAC units. Balanced allocation between groups (1:1:1). The minimum sample size required is 23 participants per group, considering an estimated loss or dropout rate of 15-20%, the sample size was increased to 27- 30 participants per group.
- Conditions
- Inflammation Biomarkers, Cardiometabolic Health Indicators, Antioxidant Status, Inflammation, Antioxidant Capabilities, Inflammaging
- Being tested
- RES 120, RES 250, RES 500
- Keywords
- Resveratrol, inflammation, inflammaging, antioxidant, cardiometabolic health, nutritional intervention
- Medical subject headings
- Inflammation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
RES 120Dietary supplement
Also called Nuvaoxi
This grape pomace bar have 120 mg of total polyphenols contents
RES 250Dietary supplement
Also called Nuvaoxi 250
This grape pomace bar is enriched with resveratrol until reach 250 mg of total polyphenols contents
RES 500Dietary supplement
Also called Nuvaoxi 500
This grape pomace bar is enriched with resveratrol until reach 500 mg of total polyphenols contents
| Study group | Role | What they receive |
|---|---|---|
| RES 120 | Sham comparator | This is the control group Receives: Dietary Supplement: RES 120 |
| RES 250 | Experimental | This is the experimental group 1 Receives: Dietary Supplement: RES 250 |
| RES 500 | Experimental | This is the experimental group 2 Receives: Dietary Supplement: RES 500 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Inflammatory biomarkers: Total plasma antioxidant capacity (µmol/L).
The total plasma antioxidant capacity by Ferric Reducing Antioxidant Power will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Inflammatory Biomarkers: Ultra-sensitivity CRP (mg/L).
The ultra-sensitivity CRP by Elisa test will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Inflammatory Biomarkers: IL-6 (pg/mL).
The IL-6 by Elisa test will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Inflammatory Biomarkers: Plasma malondialdehyde (µmol/L).
The plasma malondialdehyde by TBARS/HPLC method will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Inflammatory Biomarkers: TNF-alfa (pg/mL).
The TNF-alfa by Elisa test will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Inflammatory Biomarkers: Advanced glycation end-products (AGEs) in 1 to 5 units.
The AGEs will assess with non-invasive fluorescence pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Secondary outcomes (16)
Cardiometabolic Parameters: Body weight (kg).
Body weight will assess with electrical bioimpedance pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Body mass index-BMI (kg/m2).
The BMI will assess with electrical bioimpedance pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Basal metabolic rate (kcal).
The basal metabolic rate will assess with electrical bioimpedance pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Fat mass (kg, %).
The fat mass will assess with electrical bioimpedance pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Skeletal muscle mass (kg).
The skeletal muscle mass will assess with electrical bioimpedance pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Waist-to-hip ratio.
The waist-to-hip ratio will assess with electrical bioimpedance pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Handgrip strength (kg).
The handgrip strength will assess with dynamometry pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: 30-second sit-to-stand test (n° of repetitions achieved).
The 30-second sit-to-stand test will assess with a 43 cm height chair pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: HRV, RMSSD and SDNN in (ms).
The heart rate variability will assess in 10 minutes with continuous recording of the resting electrocardiographic tracing pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: PNN50 (%).
The heart rate variability will assess in 10 minutes with continuous recording of the resting electrocardiographic tracing pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Insuline (µIU/mL).
The fasting insulin by immunoassay will assess by a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Glucose (mg/dL).
The fasting glucose by enzymatic method will assess by a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: HOMA-IR (index).
The HOMA-IR (calculated by fasting glucose x fasting insulin/405) will assess by a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Lipid profile (mg/dL).
The lipid profile: total cholesterol, LDL, HDL and Triglycerides by enzymatic method will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Liver profile (U/L).
The liver profile: ALS, AST, GGT: by enzymatic method will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Blood pressure (mmHg)
The systolic and diastolic blood pressure will assess with a sphygmomanometer pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on cardiometabolic parameters in community-dwelling adults.
Measured: From enrollment to the end of treatment at 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start1 Jun 2026 (estimated)
- Primary completion30 Nov 2026 (estimated)
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (8)Papers the sponsor has linked to this study.
- Other trials for Inflammation BiomarkersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This Clinical Trial will be carried out with 3 parallel arms.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 75 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Center for Research and Innovation Viña Concha y Toro
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Universidad Católica del Maule
- Responsible party
- Sponsor
- Investigators
- Gerard Casaubon Cruzat, Study director, Center for Research and Innovation Viña Concha y Toro
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07395921
- Sponsor's protocol ID
- ECA Resveratrol - FIC
- Acronym
- RESINCA
- Status last verified
- May 2026
- First submitted
- 16 Jan 2026
- Last updated
- 19 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: In order to protect the privacy, data will be stored and coded. At the end of the study, data may be available upon a reasonable request and ensuring the participants' data confidentiality will be preserved.
Publications
Chiva-Blanch G, Badimon L. Effects of Polyphenol Intake on Metabolic Syndrome: Current Evidences from Human Trials. Oxid Med Cell Longev. 2017;2017:5812401. doi: 10.1155/2017/5812401. Epub 2017 Aug 15.
PubMed 28894509Breuss JM, Atanasov AG, Uhrin P. Resveratrol and Its Effects on the Vascular System. Int J Mol Sci. 2019 Mar 27;20(7):1523. doi: 10.3390/ijms20071523.
PubMed 30934670Huang H, Chen G, Liao D, Zhu Y, Pu R, Xue X. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev. 2016 Dec;17(12):1329-1340. doi: 10.1111/obr.12458. Epub 2016 Jul 26.
PubMed 27456934Springer M, Moco S. Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity. Nutrients. 2019 Jan 11;11(1):143. doi: 10.3390/nu11010143.
PubMed 30641865Pastor RF, Restani P, Di Lorenzo C, Orgiu F, Teissedre PL, Stockley C, Ruf JC, Quini CI, Garcia Tejedor N, Gargantini R, Aruani C, Prieto S, Murgo M, Videla R, Penissi A, Iermoli RH. Resveratrol, human health and winemaking perspectives. Crit Rev Food Sci Nutr. 2019;59(8):1237-1255. doi: 10.1080/10408398.2017.1400517. Epub 2017 Dec 5.
PubMed 29206058Chudzinska M, Rogowicz D, Wolowiec L, Banach J, Sielski S, Bujak R, Sinkiewicz A, Grzesk G. Resveratrol and cardiovascular system-the unfulfilled hopes. Ir J Med Sci. 2021 Aug;190(3):981-986. doi: 10.1007/s11845-020-02441-x. Epub 2020 Nov 21.
PubMed 33219913Hou CY, Tain YL, Yu HR, Huang LT. The Effects of Resveratrol in the Treatment of Metabolic Syndrome. Int J Mol Sci. 2019 Jan 28;20(3):535. doi: 10.3390/ijms20030535.
PubMed 30695995Mousavi SM, Milajerdi A, Sheikhi A, Kord-Varkaneh H, Feinle-Bisset C, Larijani B, Esmaillzadeh A. Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. Obes Rev. 2019 Mar;20(3):487-498. doi: 10.1111/obr.12775. Epub 2018 Dec 5.
PubMed 30515938
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Resveratrol Supplementation on Inflammatory Biomarkers and Cardiometabolic Parameters in Community-dwelling Adults. (RESINCA-trial)
- ClinicalTrials.gov ID
- NCT07395921
- Acronym / sponsor ID
- RESINCA / ECA Resveratrol - FIC
- Conditions
- Inflammation Biomarkers, Cardiometabolic Health Indicators, Antioxidant Status, Inflammation, Antioxidant Capabilities, Inflammaging
- Keywords
- Resveratrol, inflammation, inflammaging, antioxidant, cardiometabolic health, nutritional intervention
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 75 participants (estimated)
- Lead sponsor
- Center for Research and Innovation Viña Concha y ToroIndustry (pharma, biotech, devices)
- Collaborators
- Universidad Católica del Maule
- Study start
- 1 Jun 2026 (estimated)
- Primary completion
- 30 Nov 2026 (estimated)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers and cardiometabolic parameters in community-dwelling adults
Detailed description
Three groups will be studied: control group (RES 120), experimental group 1 (RES 250) and experimental group 2 (RES 500).
During 8 weeks the RES 120 group will received daily one grape pomace bars with 120 mg of total polyphenols contents (TPC), the RES 250 group will received daily one grape pomace bars enriched with resveratrol until reach 250 mg of TPC and the RES 500 group will received daily one grape pomace bars enriched with resveratrol until reach 500 mg of TPC.
Outcomes will be assessed at baseline and after 8 weeks.
At the end of the study, the groups that shows less o no effects will be invited to enjoy the bar showing to be more effective.
Primary outcomes are: Total plasma antioxidant capacity (TAC), ultra-sensitivity CRP, IL-6, TNF-alfa, plasma malondialdehyde and AGEs.
Secondary outcomes are: body weight, Body Mass Index (BMI), basal metabolic rate, fat mass, skeletal muscle mass, and waist-to-hip ratio. Handgrip strength, 30-second sit-to-stand test, and heart rate variability. Fasting insulin, fasting glucose, HOMA-IR. Lipid profile, liver profile, blood pressure.
All procedures will be performed at the clinical simulation center of the Faculty of Medicine of the Catholic University of Maule.
The sample size was estimated under the following criteria, using G*Power software (version 3.1):
Primary outcome: Total Plasma Antioxidant Capacity (TAC). Type of comparison: differences between parallel groups. Level of significance (α): 0.05 (bilateral). Stat (1 - β): 80%. Minimum expected difference (Δ): 0.25 TAC units. Standard deviation (σ): 0.30 TAC units. Balanced allocation between groups (1:1:1). The minimum sample size required is 23 participants per group, considering an estimated loss or dropout rate of 15-20%, the sample size was increased to 27- 30 participants per group.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 3
- Model description
- This Clinical Trial will be carried out with 3 parallel arms.
| Arm | Type | Receives |
|---|---|---|
| RES 120 | Sham comparator | Dietary Supplement: RES 120This is the control group |
| RES 250 | Experimental | Dietary Supplement: RES 250This is the experimental group 1 |
| RES 500 | Experimental | Dietary Supplement: RES 500This is the experimental group 2 |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Comunnity-dwelling persons.
- Any ethnicity.
- With willingness to consume the bar daily during the intervention period.
Key exclusion criteria (10 listed)
- Allergy/intolerance to ingredients in the bar.
- Pregnancy or breastfeeding.
- Use of antioxidant/polymeroid supplements in the last 4 weeks.
- Unstable chronic diseases (e.g., severe liver failure, advanced kidney failure, active cancer).
- Persons in treatments that strongly interfere with polyphenol metabolism (e.g., antibiotics, anti-inflammatories, corticosteroids, anti-allergy medication).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| RES 120Also: NuvaoxiThis grape pomace bar have 120 mg of total polyphenols contents | Dietary supplement | RES 120 |
| RES 250Also: Nuvaoxi 250This grape pomace bar is enriched with resveratrol until reach 250 mg of total polyphenols contents | Dietary supplement | RES 250 |
| RES 500Also: Nuvaoxi 500This grape pomace bar is enriched with resveratrol until reach 500 mg of total polyphenols contents | Dietary supplement | RES 500 |
Primary outcome
Inflammatory biomarkers: Total plasma antioxidant capacity (µmol/L).
Time frame: From enrollment to the end of treatment at 8 weeks
The total plasma antioxidant capacity by Ferric Reducing Antioxidant Power will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Inflammatory Biomarkers: Ultra-sensitivity CRP (mg/L).
Time frame: From enrollment to the end of treatment at 8 weeks
The ultra-sensitivity CRP by Elisa test will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Inflammatory Biomarkers: IL-6 (pg/mL).
Time frame: From enrollment to the end of treatment at 8 weeks
The IL-6 by Elisa test will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Inflammatory Biomarkers: Plasma malondialdehyde (µmol/L).
Time frame: From enrollment to the end of treatment at 8 weeks
The plasma malondialdehyde by TBARS/HPLC method will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Inflammatory Biomarkers: TNF-alfa (pg/mL).
Time frame: From enrollment to the end of treatment at 8 weeks
The TNF-alfa by Elisa test will assess with a blood sample pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
Inflammatory Biomarkers: Advanced glycation end-products (AGEs) in 1 to 5 units.
Time frame: From enrollment to the end of treatment at 8 weeks
The AGEs will assess with non-invasive fluorescence pre and post intervention to evaluate the effect of the supplementation of grape pomace bars enriched in resveratrol on inflammatory biomarkers in community-dwelling adults.
16 secondary outcomes
Cardiometabolic Parameters: Body weight (kg).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Body mass index-BMI (kg/m2).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Basal metabolic rate (kcal).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Fat mass (kg, %).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Skeletal muscle mass (kg).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Waist-to-hip ratio.
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: Handgrip strength (kg).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic Parameters: 30-second sit-to-stand test (n° of repetitions achieved).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: HRV, RMSSD and SDNN in (ms).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: PNN50 (%).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Insuline (µIU/mL).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Glucose (mg/dL).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: HOMA-IR (index).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Lipid profile (mg/dL).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Liver profile (U/L).
Time frame: From enrollment to the end of treatment at 8 weeks
Cardiometabolic parameters: Blood pressure (mmHg)
Time frame: From enrollment to the end of treatment at 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Background: PubMed 28894509Chiva-Blanch G, Badimon L. Effects of Polyphenol Intake on Metabolic Syndrome: Current Evidences from Human Trials. Oxid Med Cell Longev. 2017;2017:5812401. doi: 10.1155/2017/5812401. Epub 2017 Aug 15.
- Background: PubMed 30934670Breuss JM, Atanasov AG, Uhrin P. Resveratrol and Its Effects on the Vascular System. Int J Mol Sci. 2019 Mar 27;20(7):1523. doi: 10.3390/ijms20071523.
- Background: PubMed 27456934Huang H, Chen G, Liao D, Zhu Y, Pu R, Xue X. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev. 2016 Dec;17(12):1329-1340. doi: 10.1111/obr.12458. Epub 2016 Jul 26.
- Background: PubMed 30641865Springer M, Moco S. Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity. Nutrients. 2019 Jan 11;11(1):143. doi: 10.3390/nu11010143.
- Background: PubMed 29206058Pastor RF, Restani P, Di Lorenzo C, Orgiu F, Teissedre PL, Stockley C, Ruf JC, Quini CI, Garcia Tejedor N, Gargantini R, Aruani C, Prieto S, Murgo M, Videla R, Penissi A, Iermoli RH. Resveratrol, human health and winemaking perspectives. Crit Rev Food Sci Nutr. 2019;59(8):1237-1255. doi: 10.1080/10408398.2017.1400517. Epub 2017 Dec 5.
- Background: PubMed 33219913Chudzinska M, Rogowicz D, Wolowiec L, Banach J, Sielski S, Bujak R, Sinkiewicz A, Grzesk G. Resveratrol and cardiovascular system-the unfulfilled hopes. Ir J Med Sci. 2021 Aug;190(3):981-986. doi: 10.1007/s11845-020-02441-x. Epub 2020 Nov 21.
- Background: PubMed 30695995Hou CY, Tain YL, Yu HR, Huang LT. The Effects of Resveratrol in the Treatment of Metabolic Syndrome. Int J Mol Sci. 2019 Jan 28;20(3):535. doi: 10.3390/ijms20030535.
- Background: PubMed 30515938Mousavi SM, Milajerdi A, Sheikhi A, Kord-Varkaneh H, Feinle-Bisset C, Larijani B, Esmaillzadeh A. Resveratrol supplementation significantly influences obesity measures: a systematic review and dose-response meta-analysis of randomized controlled trials. Obes Rev. 2019 Mar;20(3):487-498. doi: 10.1111/obr.12775. Epub 2018 Dec 5.
- Individual participant dataSharing planned: No. In order to protect the privacy, data will be stored and coded. At the end of the study, data may be available upon a reasonable request and ensuring the participants' data confidentiality will be preserved.
Related trials for Inflammation Biomarkers
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
RecruitingObservational study
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
Pulmonary Disease, Pulmonary Hypertension
RecruitingObservational study
Descriptive Study of Circulating Gene or Protein Inflammatory Biomarkers and Bioimpedance Parameters in a Population of Patients Hospitalized for Decompensated Heart Failure With Preserved or Mildly Reduced Cardiac Function
Inflammation Biomarkers, Heart Failure
RecruitingObservational study
Oxidative Stress and Inflammatory Biomarkers in Gaucher Disease
Gaucher Disease Type I, Oxidative Stress
Active, not recruitingObservational study
Epigenetic Changes in Long COVID Patients
Long COVID-19 Syndrome, Long COVID Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Gerard Casaubon Cruzat study director
Center for Research and Innovation Viña Concha y Toro
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing RES 120, RES 250 and RES 500 in people with Inflammation Biomarkers and Cardiometabolic Health Indicators, run by Center for Research and Innovation Viña Concha y Toro at 1 site in Chile.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ileana González Bonet, Dr (+56 71 2986000, ileanag@ucm.cl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Inflammatory biomarkers: Total plasma antioxidant capacity (µmol/L). (time frame: From enrollment to the end of treatment at 8 weeks). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07395921, which also lists 8 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.